Rising to the innovation challenge
This article was originally published in Scrip
The past few weeks have seen a flurry of moves to shore up innovation in pharmaceutical and medical research in the EU. Despite the deepening economic gloom, and as member states pare public spending to the bone, governments and institutions appear to be looking beyond the immediate future with pledges on funding incentives, new innovation centres, greater use of public-private partnerships (PPPs) and the like.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.